Abstract
The use of conventional therapeutic approaches in patients with lymphoma demonstrates significant drug resistance leading to poor prognosis with reduced median survival period. T-cell immunotherapy has diverted huge attention of the researchers in recent times to engage in the stated research studies in the pool of chemotherapy-refractory lymphoma patients. B-cell antigen CD19-targeted chimeric antigen receptor (CAR) T-cell products are approved for the treatment of non-Hodgkin B-cell refracting or relapsing lymphoma. The aim of this article is to give an idea about the use of FDA-approved anti-cancer gene therapy, Axicabtagene ciloleucel, marketed under the name of Yescarta®. Axicabtagene ciloleucel is developed from the patients’ mononuclear peripheral blood cells during which T cells are orchestrated to articulate a CAR that diverts them to identify CD19-expressing cells. It is used in patients with non-Hodgkin B-cell refracting or relapsing lymphoma who had no response to prior therapeutic regiment involving the use of chemotherapeutics. Here, we review the mode of action, safety, and efficacy of Yescarta.
Highlights
BackgroundIn the United States, lymphoma is known to be the most prevalent hematological malignancy, which accounts for 3.5% of all cancer-related death
Combinatorial therapies involving radiotherapy, immunotherapy/chemotherapy, and stem cell hematopoietic transplantation are the conventional therapies for the treatment of lymphoma
Drug resistance to conventional therapies develops in approximately 20% of all lymphoma patients, resulting in a decrease in therapeutic efficacy [2,3]
Summary
BackgroundIn the United States, lymphoma is known to be the most prevalent hematological malignancy, which accounts for 3.5% of all cancer-related death. The most common form of lymphoma, B-cell lymphoma, can be further divided into Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). NHL, accounting for approximately 90% of cases of B-cell lymphoma, is differentiated into forms such as diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma [1]. Drug resistance to conventional therapies develops in approximately 20% of all lymphoma patients, resulting in a decrease in therapeutic efficacy [2,3]. In such a scenario, new therapies need to be designed, which can boost therapeutic outcomes in patients with recurrent or treatment-refractory lymphoma
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
